Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant plus palbociclib versus letrozole plus palbociclib in first-line ER-positive, HER2-negative advanced breast cancer
MOH_2020-12-09_009425Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing giredestrant + palbociclib with Control: letrozole + palbociclib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2020; status: active, not recruiting.
02
Drugs
giredestrantpalbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-12-09_009425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-09_009425.